Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: analysis of a nationwide registry

Letter Immunology

The Right Time for Steroids in COVID-19

Ana Fernandez-Cruz et al.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Letter Rheumatology

Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab

Hendrik Schulze-Koops et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Jesus Rodriguez-Bano et al.

Summary: This study suggests that tocilizumab may help reduce the risk of intubation or death in COVID-19 patients with a hyperinflammatory state. Corticosteroid treatment is less effective than tocilizumab, with combination therapy falling in between.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

添加到收藏夹

Article Rheumatology

Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

Florence Aeschlimann et al.

Summary: In this French cohort study of RMD COVID-19 patients, older age, male gender, obesity, and hypertension were found to be associated with severe COVID-19, similar to the general population. Patients with iRMD on corticosteroids, but not methotrexate, tumor necrosis factor alpha, and interleukin-6 inhibitors, were more likely to develop severe COVID-19. Unlike common comorbidities, such as obesity, cardiovascular or lung diseases, the risk of death in patients with iRMD was not significantly increased.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study

Luca S. Belli et al.

Summary: Despite concerns, data from adult liver transplant recipients with COVID-19 infection in Europe shows that age over 70, diabetes, and chronic kidney disease are associated with increased risk of death, while the use of tacrolimus may improve survival rates in these patients.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease: A pilot study

J. L. Galvez-Romero et al.

Summary: In COVID-19 patients, adding CsA as an adjuvant to steroid treatment can improve outcomes and reduce mortality, especially in those with moderate to severe disease. Further controlled clinical trials are needed for confirmation.

JOURNAL OF INTERNAL MEDICINE (2021)

添加到收藏夹

Article Immunology

The Importance of Understanding the Stages of COVID-19 in Treatment and Trials

Daniel O. Griffin et al.

AIDS REVIEWS (2021)

添加到收藏夹

Letter Gastroenterology & Hepatology

Tacrolimus Use and COVID-19 Infection in Patients After Solid Organ Transplantation

Saifu Yin et al.

GASTROENTEROLOGY (2021)

添加到收藏夹

Review Infectious Diseases

COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients

Jennifer A. Belsky et al.

Summary: Severe COVID-19 caused by SARS-CoV-2 has a greater impact on immunocompromised patients such as cancer and solid organ transplant recipients, leading to higher comorbidities and poorer hospital outcomes. However, hematopoietic cell transplant recipients and pediatric cancer patients tend to have clinical presentations and outcomes similar to the general population.

JOURNAL OF INFECTION (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

The time to offer treatments for COVID-19

Binh T. Ngo et al.

Summary: Current treatments for COVID-19 mainly focus on hospitalized patients in late stage, with limited authorized drugs available. Vaccines and antibodies are highly antigen specific.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

添加到收藏夹

Article Medicine, General & Internal

Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry

Maria del Mar Ayala Gutierrez et al.

Summary: The analysis of hospitalized COVID-19 patients with autoimmune diseases (ADs) compared to the general population did not show a significant difference in overall prognosis, but individual diseases may have varying effects. Immunosuppressive/immunoregulatory treatments (IST) prior to admission had variable effects on outcomes.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

In-hospital mortality among immunosuppressed patients with COVID-19: Analysis from a national cohort in Spain

Ines Suarez-Garcia et al.

Summary: This study found that immunosuppressed patients hospitalized with COVID-19 have a higher risk of complications and death compared to non-immunosuppressed patients.

PLOS ONE (2021)

添加到收藏夹

Article Medicine, General & Internal

Severe Lymphopenia as a Predictor of COVID-19 Mortality in Immunosuppressed Patients

Maria Martinez-Urbistondo et al.

Summary: Immunosuppression is an independent risk factor for mortality in COVID-19 patients, with severe lymphopenia playing a key role in immunocompromised individuals. Prompt identification of severe lymphopenia is critical in these patients. Immunosuppression remains significantly associated with a higher mortality rate even after adjustment for other factors.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Pharmacology & Pharmacy